TY - JOUR T1 - ▼ Safinamide for Parkinson’s disease JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 54 LP - 57 DO - 10.1136/dtb.2018.5.0623 VL - 56 IS - 5 A2 - , Y1 - 2018/05/01 UR - http://dtb.bmj.com/content/56/5/54.abstract N2 - ▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor. ER -